Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sigurd Folkvord

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Patient Education and Counseling|October 26, 2005
Male infertility in ZimbabweSigurd Folkvord, Oystein Andreas Odegaard, Johanne Sundby
International Journal of Radiation Oncology, Biology, Physics|May 12, 2009
Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation statusSigurd Folkvord, Anne Hansen Ree, Torbjørn Furre, et al.
Neoplasia (New York, N.Y.)|May 31, 2007
Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude miceTherese Seierstad, Sigurd Folkvord, Kathrine Røe, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 17, 2007
Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?Sigurd Folkvord, Kjersti Flatmark, Therese Seierstad, et al.
Angiogenesis|August 12, 2011
Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic disseminationMarie Grøn Saelen, Kjersti Flatmark, Sigurd Folkvord, et al.
Critical Reviews in Oncology/Hematology|January 28, 2015
Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapiesAnne Hansen Ree, Kjersti Flatmark, Marie Grøn Saelen, et al.
The Lancet. Oncology|April 10, 2010
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 studyAnne Hansen Ree, Svein Dueland, Sigurd Folkvord, et al.
Radiation Oncology (London, England)|August 5, 2006
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibitionKjersti Flatmark, Ragnhild V Nome, Sigurd Folkvord, et al.
Anticancer Research|July 11, 2006
DNA damage responses in cell cycle G2 phase and mitosis--tracking and targetingAnne Hansen Ree, Trond Stokke, Ase Bratland, et al.
International Journal of Radiation Oncology, Biology, Physics|August 3, 2010
Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profilingSigurd Folkvord, Kjersti Flatmark, Svein Dueland, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Patient Education and Counseling|October 26, 2005
Male infertility in ZimbabweSigurd Folkvord, Oystein Andreas Odegaard, Johanne Sundby
International Journal of Radiation Oncology, Biology, Physics|May 12, 2009
Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation statusSigurd Folkvord, Anne Hansen Ree, Torbjørn Furre, et al.
Neoplasia (New York, N.Y.)|May 31, 2007
Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude miceTherese Seierstad, Sigurd Folkvord, Kathrine Røe, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 17, 2007
Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?Sigurd Folkvord, Kjersti Flatmark, Therese Seierstad, et al.
Angiogenesis|August 12, 2011
Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic disseminationMarie Grøn Saelen, Kjersti Flatmark, Sigurd Folkvord, et al.
Critical Reviews in Oncology/Hematology|January 28, 2015
Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapiesAnne Hansen Ree, Kjersti Flatmark, Marie Grøn Saelen, et al.
The Lancet. Oncology|April 10, 2010
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 studyAnne Hansen Ree, Svein Dueland, Sigurd Folkvord, et al.
Radiation Oncology (London, England)|August 5, 2006
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibitionKjersti Flatmark, Ragnhild V Nome, Sigurd Folkvord, et al.
Anticancer Research|July 11, 2006
DNA damage responses in cell cycle G2 phase and mitosis--tracking and targetingAnne Hansen Ree, Trond Stokke, Ase Bratland, et al.
International Journal of Radiation Oncology, Biology, Physics|August 3, 2010
Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profilingSigurd Folkvord, Kjersti Flatmark, Svein Dueland, et al.
Pageof 1